★ Analysts see FY2028 revenue reaching $21.3B — +27.7% growth in a single year.
Why Revenue Could Accelerate
01New customer wins and molecule additions - particularly regulated market approvals (US FDA, EU) that validate quality systems and open addressable market
02Capacity utilization rates at existing and new facilities - the company is in heavy expansion mode with negative FCF, so ramp-up timelines drive earnings inflection
03China+1 sourcing trends - pharmaceutical companies diversifying supply chains away from China due to geopolitical and quality concerns
04Raw material cost pass-through effectiveness - ability to maintain gross margins during input cost volatility
05Regulatory inspection outcomes - US FDA or EU GMP observations can halt shipments and materially impact revenue
growth - The stock attracts growth investors focused on India's specialty chemicals opportunity and China+1 supply chain themes.
Rising rates have moderate negative impact through two channels: (1) The company is in heavy capex mode with $1.9B investment…
Watch on earnings: US FDA and EU GMP inspection outcomes and regulatory compliance status across all manufacturing sites, Quarterly capacity utilization rates and timeline updates for new facility commissioning (particularly fluorination and hydrogenation units), Gross margin trends and raw material cost pass-through effectiveness - watch for 100-200bp quarterly swings.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $16.6B to $21.3B as new customer wins and molecule additions - particularly regulated market approvals (us fda.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
